The minimal clinically important difference in allergic rhinitis

被引:107
作者
Barnes, M. L. [1 ]
Vaidyanathan, S. [1 ]
Williamson, P. A. [1 ]
Lipworth, B. J. [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Asthma & Allergy Res Grp, Dept Med & Therapeut, Dundee DD1 9SY, Scotland
关键词
allergic rhinitis; Mini Rhinoconjunctivitis Quality of Life Questionnaire; minimal clinically important difference; peak nasal inspiratory flow; total nasal symptom score; COMBINED MEDIATOR BLOCKADE; AQUEOUS NASAL SPRAY; NITRIC-OXIDE; ASTHMA; FLUTICASONE; DOMICILIARY; CHALLENGE; THERAPY; IMPACT;
D O I
10.1111/j.1365-2222.2009.03381.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
P>Background When presented with results from clinical measurements or research findings, clinicians must first make an interpretation of their importance, not only in statistical terms, but also the 'clinical importance' given the size of the change observed. To do this, they require an understanding of the relationship between their outcome measures, and the patient's perception of change. The minimal clinically important difference (MCID) illustrates this relationship by calculating the smallest change in a given outcome that is meaningful to a patient. There are few reports of calculated MCIDs in the Rhinology literature. Objective To calculate MCIDs for common subjective and objective outcome measures in allergic rhinitis (AR). Methods Nine randomized, blinded, placebo-controlled clinical trials in intermittent and persistent AR (pooled subjects, n=204) were analysed using anchor- and distribution-based approaches, applying regression and meta-analysis techniques. Results MCIDs were obtained for the Mini Rhinoconjunctivitis Quality of Life Questionnaire: 0.4 units, peak nasal inspiratory flow: 5 L/min and total nasal symptoms score: 0.55 units. Nasal NO measurement changes had no correlation with patient perceptions of benefit. Conclusion Estimates of MCIDs were obtained for common subjective and objective rhinological outcomes. MCIDs can and should be applied by physicians interpreting research findings, as well as researchers reporting their findings. We can then be confident that our changes in practice will be of perceptible benefit to the patient. Cite this as: M. L. Barnes, S. Vaidyanathan, P. A. Williamson and B. J. Lipworth, Clinical & Experimental Allergy, 2010 (40) 242-250.
引用
收藏
页码:242 / 250
页数:9
相关论文
共 38 条
[1]   ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005 [J].
American Thoracic Society ;
European Respiratory Society .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (08) :912-930
[2]  
Arnal JF, 1997, CLIN EXP ALLERGY, V27, P358
[3]   Effect of topical steroids on nasal nitric oxide production in children with perennial allergic rhinitis: a pilot study [J].
Baraldi, E ;
Azzolin, NM ;
Carra, S ;
Dario, C ;
Marchesini, L ;
Zacchello, F .
RESPIRATORY MEDICINE, 1998, 92 (03) :558-561
[4]   A proof-of-concept study to assess the putative dose response to topical corticosteroid in persistent allergic rhinitis using adenosine monophosphate challenge [J].
Barnes, M. L. ;
Menzies, D. ;
Nair, A. R. ;
Hopkinson, P. J. ;
Lipworth, B. J. .
CLINICAL AND EXPERIMENTAL ALLERGY, 2007, 37 (05) :696-703
[5]   Combined mediator blockade or topical steroid for treating the unified allergic airway [J].
Barnes, M. L. ;
Menzies, D. ;
Fardon, T. C. ;
Burns, P. ;
Wilson, A. M. ;
Lipworth, B. J. .
ALLERGY, 2007, 62 (01) :73-80
[6]   Effects of intranasal corticosteroid on nasal adenosine monophosphate challenge in persistent allergic rhinitis [J].
Barnes, M. L. ;
Biallosterski, B. T. ;
Fujihara, S. ;
Gray, R. D. ;
Fardon, T. C. ;
Lipworth, B. J. .
ALLERGY, 2006, 61 (11) :1319-1325
[7]   Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis [J].
Barnes, ML ;
Ward, JH ;
Fardon, TC ;
Lipworth, BJ .
CLINICAL AND EXPERIMENTAL ALLERGY, 2006, 36 (05) :676-684
[8]   Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen) [J].
Bousquet, J. ;
Khaltaev, N. ;
Cruz, A. A. ;
Denburg, J. ;
Fokkens, W. J. ;
Togias, A. ;
Zuberbier, T. ;
Baena-Cagnani, C. E. ;
Canonica, G. W. ;
van Weel, C. ;
Agache, I. ;
Ait-Khaled, N. ;
Bachert, C. ;
Blaiss, M. S. ;
Bonini, S. ;
Boulet, L. -P. ;
Bousquet, P. -J. ;
Camargos, P. ;
Carlsen, K. -H. ;
Chen, Y. ;
Custovic, A. ;
Dahl, R. ;
Demoly, P. ;
Douagui, H. ;
Durham, S. R. ;
van Wijk, R. Gerth ;
Kalayci, O. ;
Kaliner, M. A. ;
Kim, Y. -Y. ;
Kowalski, M. L. ;
Kuna, P. ;
Le, L. T. T. ;
Lemiere, C. ;
Li, J. ;
Lockey, R. F. ;
Mavale-Manuel, S. ;
Meltzer, E. O. ;
Mohammad, Y. ;
Mullol, J. ;
Naclerio, R. ;
Hehir, R. E. O. ;
Ohta, K. ;
Ouedraogo, S. ;
Palkonen, S. ;
Papadopoulos, N. ;
Passalacqua, G. ;
Pawankar, R. ;
Popov, T. A. ;
Rabe, K. F. ;
Rosado-Pinto, J. .
ALLERGY, 2008, 63 :8-+
[9]   Methodology for development of the Allergic Rhinitis and its Impact on Asthma Guideline 2008 update [J].
Brozek, J. L. ;
Baena-Cagnani, C. E. ;
Bonini, S. ;
Canonica, G. W. ;
Rasi, G. ;
van Wijk, R. G. ;
Zuberbier, T. ;
Guyatt, G. ;
Bousquet, J. ;
Schuenemann, H. J. .
ALLERGY, 2008, 63 (01) :38-46
[10]   How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure [J].
Brozek, Jan L. ;
Guyatt, Gordon H. ;
Schuenemann, Holger J. .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)